ATE181669T1 - Verwendung von remacemid zur behandlung des morbus parkinson - Google Patents
Verwendung von remacemid zur behandlung des morbus parkinsonInfo
- Publication number
- ATE181669T1 ATE181669T1 AT93911903T AT93911903T ATE181669T1 AT E181669 T1 ATE181669 T1 AT E181669T1 AT 93911903 T AT93911903 T AT 93911903T AT 93911903 T AT93911903 T AT 93911903T AT E181669 T1 ATE181669 T1 AT E181669T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- remacemid
- treat parkinson
- parkinson
- remacemide
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 abstract 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 229950000659 remacemide Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929209599A GB9209599D0 (en) | 1992-05-02 | 1992-05-02 | Novel therapy for the treatment of parkinsons disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE181669T1 true ATE181669T1 (de) | 1999-07-15 |
Family
ID=10714969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93911903T ATE181669T1 (de) | 1992-05-02 | 1993-04-30 | Verwendung von remacemid zur behandlung des morbus parkinson |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0637956B1 (de) |
| JP (1) | JP3542801B2 (de) |
| KR (1) | KR950701216A (de) |
| AT (1) | ATE181669T1 (de) |
| CA (1) | CA2134783C (de) |
| DE (1) | DE69325512T2 (de) |
| DK (1) | DK0637956T3 (de) |
| ES (1) | ES2135476T3 (de) |
| GB (1) | GB9209599D0 (de) |
| GR (1) | GR3031320T3 (de) |
| HU (1) | HU211305A9 (de) |
| IL (1) | IL105569A (de) |
| NZ (2) | NZ299042A (de) |
| SG (1) | SG49202A1 (de) |
| WO (1) | WO1993021910A1 (de) |
| ZA (1) | ZA933086B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025369A (en) * | 1996-05-03 | 2000-02-15 | The Board Of Regents Of The University Nebraska | N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis |
| RU2170576C1 (ru) * | 1999-11-15 | 2001-07-20 | Государственное учреждение науки Институт токсикологии | Гидрохлориды замещенных ацетиленовых аминоспиртов, обладающие антигалоперидоловой активностью |
| IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
| WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| JP2011529923A (ja) | 2008-08-06 | 2011-12-15 | ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド | 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU639722B2 (en) * | 1989-10-27 | 1993-08-05 | Astra Aktiebolag | Use of arylalkylamides in the treatment of neurodegenerative diseases |
| DE3940410A1 (de) * | 1989-12-04 | 1991-06-06 | Schering Ag | Neue verwendung von nmda-rezeptor-antagonisten |
-
1992
- 1992-05-02 GB GB929209599A patent/GB9209599D0/en active Pending
-
1993
- 1993-04-30 IL IL105569A patent/IL105569A/xx not_active IP Right Cessation
- 1993-04-30 CA CA002134783A patent/CA2134783C/en not_active Expired - Fee Related
- 1993-04-30 KR KR1019940703908A patent/KR950701216A/ko not_active Ceased
- 1993-04-30 DK DK93911903T patent/DK0637956T3/da active
- 1993-04-30 AT AT93911903T patent/ATE181669T1/de not_active IP Right Cessation
- 1993-04-30 EP EP93911903A patent/EP0637956B1/de not_active Expired - Lifetime
- 1993-04-30 ES ES93911903T patent/ES2135476T3/es not_active Expired - Lifetime
- 1993-04-30 NZ NZ299042A patent/NZ299042A/en not_active IP Right Cessation
- 1993-04-30 ZA ZA933086A patent/ZA933086B/xx unknown
- 1993-04-30 JP JP51908793A patent/JP3542801B2/ja not_active Expired - Fee Related
- 1993-04-30 NZ NZ252728A patent/NZ252728A/en not_active IP Right Cessation
- 1993-04-30 SG SG1996007583A patent/SG49202A1/en unknown
- 1993-04-30 DE DE69325512T patent/DE69325512T2/de not_active Expired - Fee Related
- 1993-04-30 WO PCT/GB1993/000908 patent/WO1993021910A1/en not_active Ceased
-
1995
- 1995-06-23 HU HU95P/P00425P patent/HU211305A9/hu unknown
-
1999
- 1999-09-23 GR GR990402420T patent/GR3031320T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR950701216A (ko) | 1995-03-23 |
| NZ299042A (en) | 2000-07-28 |
| IL105569A (en) | 1997-11-20 |
| IL105569A0 (en) | 1993-08-18 |
| DE69325512D1 (de) | 1999-08-05 |
| EP0637956A1 (de) | 1995-02-15 |
| GR3031320T3 (en) | 1999-12-31 |
| HU211305A9 (en) | 1995-11-28 |
| CA2134783A1 (en) | 1993-11-11 |
| JP3542801B2 (ja) | 2004-07-14 |
| GB9209599D0 (en) | 1992-06-17 |
| NZ252728A (en) | 1996-11-26 |
| DE69325512T2 (de) | 1999-12-16 |
| JPH07506105A (ja) | 1995-07-06 |
| ZA933086B (en) | 1993-11-01 |
| SG49202A1 (en) | 1998-05-18 |
| DK0637956T3 (da) | 1999-11-22 |
| CA2134783C (en) | 2002-08-13 |
| EP0637956B1 (de) | 1999-06-30 |
| ES2135476T3 (es) | 1999-11-01 |
| WO1993021910A1 (en) | 1993-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| ATE241365T1 (de) | Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen | |
| DE68919358D1 (de) | Zusammensetzung zur behandlung der schizophrenie. | |
| DE69230046D1 (de) | 2-Bromomelatonin zur Behandlung von Schlafstörungen | |
| SE9401406D0 (sv) | Pharmaceutical products for curing tumourous diseases and process for preparing same | |
| ATE209908T1 (de) | RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN | |
| PT1001775E (pt) | Medicamento contendo ioimbina e arginina para tratamento de disfuncao erectil | |
| ATE181669T1 (de) | Verwendung von remacemid zur behandlung des morbus parkinson | |
| PT983300E (pt) | Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia | |
| DE69300037D1 (de) | Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria. | |
| NZ268039A (en) | Use of efaroxan in treating parkinson's disease | |
| NO944809L (no) | Biologisk aktive ureidoderivater som er nyttig i behandling av lentivirus-indusert sykdom | |
| RU93051046A (ru) | Способ борьбы с аскосферозом и гнильцовыми болезнями пчел | |
| FR2818147B1 (fr) | Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine | |
| DE69430807D1 (de) | Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen | |
| RU93052810A (ru) | Способ лечения женского бесплодия эндокринно-воспалительного генеза | |
| RU94016144A (ru) | Средство для лечения больных болезнью рейтера | |
| DE68914886D1 (de) | Mittel zur Behandlung von Raynaud's Krankheit. | |
| EA199700034A2 (ru) | Способ в.г.соломатова коррекции энергетического состояния живого существа | |
| RU96118559A (ru) | Лекарственное средство | |
| RU93043278A (ru) | Способ лечения костномозговой формы острой лучевой болезни |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |